AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Dosage
300 mcg subcutaneous once daily
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Get Research-Grade AOD-9604
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Fat Metabolism
Stimulates lipolysis in adipose tissue through beta-3 adrenergic receptor activation.
Lipogenesis Inhibition
May reduce new fat synthesis by downregulating key lipogenic enzymes.
IGF-1 Neutral
Does not elevate IGF-1 or cause insulin resistance unlike full-length GH.
Mechanism of Action
AOD-9604 is a modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. This specific region of the GH molecule contains the lipolytic (fat-burning) domain while lacking the receptor binding regions responsible for growth-promoting and diabetogenic effects. The result is a peptide that mimics the fat metabolism effects of growth hormone without stimulating IGF-1 production, bone growth, or insulin resistance.
The primary mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) through a cAMP-dependent pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are then released into the bloodstream for oxidation by muscle and liver tissue. Simultaneously, AOD-9604 appears to inhibit lipogenesis — the synthesis of new fatty acids from non-lipid precursors — by downregulating acetyl-CoA carboxylase and fatty acid synthase activity in adipocytes.
Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor or stimulate JAK2/STAT5 signaling, which is why it avoids the IGF-1 elevation, water retention, and insulin resistance associated with exogenous GH use. However, it should be noted that AOD-9604 failed to show significant weight loss compared to placebo in Phase II/III clinical trials, raising questions about whether its in vitro lipolytic activity translates to meaningful clinical effects at the doses tested.
Regulatory Status
Not FDA approved. Failed Phase II/III trials. GRAS status as a food supplement ingredient. Available through compounding pharmacies.
Risks & Safety
Common
injection site irritation, headache, mild tiredness.
Serious
chest tightness (reported in trials), very limited clinical data on long-term effects.
Rare
allergic reactions.
Compare AOD-9604 With
Research Papers
1Published: December 31, 2025
AI Summary
A broad review explains how growth hormone secretagogues like AOD-9604 support tissue repair, inflammation control, and nerve recovery in musculoskeletal care. While animal studies look promising, human clinical trials are still lacking.
Frequently Asked Questions
What is AOD-9604?
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
What is AOD-9604 used for?
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
What is the dosage for AOD-9604?
Research: 300 mcg subcutaneous once daily in the abdominal area, on an empty stomach. Often cycled 12 weeks on, 4 weeks off.
What are the side effects of AOD-9604?
Common: injection site irritation, headache, mild tiredness. Serious: chest tightness (reported in trials), very limited clinical data on long-term effects. Rare: allergic reactions.
How does AOD-9604 work?
AOD-9604 is a modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. This specific region of the GH molecule contains the lipolytic (fat-burning) domain while lacking the receptor binding regions responsible for growth-promoting and diabetogenic effects. The result is a peptide that mimics the fat metabolism effects of growth hormone without stimulating IGF-1 production, bone growth, or insulin resistance. The primary mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) through a cAMP-dependent pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are then released into the bloodstream for oxidation by muscle and liver tissue. Simultaneously, AOD-9604 appears to inhibit lipogenesis — the synthesis of new fatty acids from non-lipid precursors — by downregulating acetyl-CoA carboxylase and fatty acid synthase activity in adipocytes. Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor or stimulate JAK2/STAT5 signaling, which is why it avoids the IGF-1 elevation, water retention, and insulin resistance associated with exogenous GH use. However, it should be noted that AOD-9604 failed to show significant weight loss compared to placebo in Phase II/III clinical trials, raising questions about whether its in vitro lipolytic activity translates to meaningful clinical effects at the doses tested.
How is AOD-9604 administered?
AOD-9604 is administered via subcutaneous injection or oral.
What is the half-life of AOD-9604?
The half-life of AOD-9604 is 1-2 hours.
Is AOD-9604 legal?
Not FDA approved. Failed Phase II/III trials. GRAS status as a food supplement ingredient. Available through compounding pharmacies.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.
CagriSema
A once-weekly injection that combines two powerful appetite-suppressing drugs — cagrilintide and semaglutide — into a single shot. By targeting two different hunger pathways in the brain simultaneously, it achieves roughly 25% body weight loss in trials, making it one of the most effective weight loss treatments ever developed. Think of it as the next generation beyond Wegovy. Still awaiting FDA approval.